Search clinical trials for: Infanrix™-IPV/Hib

Total 399 results

GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

China
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Korea, Republic of
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b
Dalhousie University
IWK Health Centre; MCM Vaccines B.V.

Completed

Interchangeability of Infanrix™ IPV/Hib and Pediacel® at 2,4 & 6 Months of Age

Infant Immunizations

Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine

Tetanus | Diphtheria | Acellular Pertussis | Haemophilus Influenzae Type b

China
GlaxoSmithKline

Completed

Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Vietnam
GlaxoSmithKline

Completed

Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

China
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Sweden
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

India
Sanofi Pasteur, a Sanofi Company

Completed

Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®

Healthy | Infant

Germany
GlaxoSmithKline

Completed

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type b

Russian Federation
GlaxoSmithKline

Withdrawn

Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b
GlaxoSmithKline

Completed

Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b (Hib)
GlaxoSmithKline

Completed

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
GlaxoSmithKline

Completed

Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.

Tetanus | Diphtheria | Acellular Pertussis

China
GlaxoSmithKline

Completed

Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule

Infections, Streptococcal

Slovakia, Sweden, Denmark, Norway
GlaxoSmithKline

Completed

Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old

Infections, Meningococcal

Austria, Greece
GlaxoSmithKline

Completed

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Streptococcus Pneumoniae Vaccines

Spain, Germany, Poland
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b (Hib)
GlaxoSmithKline

Completed

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
GlaxoSmithKline

Completed

Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule

Infections, Streptococcal

Chile
GlaxoSmithKline

Completed

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

Belgium, Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
GlaxoSmithKline

Completed

Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.

Streptococcus Pneumoniae Vaccines | Infections, Streptococcal

Spain, Greece
Sanofi Pasteur, a Sanofi Company

Completed

Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

France, Poland
GlaxoSmithKline

Terminated

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

Influenza

Norway
Sanofi Pasteur, a Sanofi Company

Completed

Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease

Pertussis | Tetanus | Diphtheria | Polio | Haemophilus Infections

United States
GlaxoSmithKline

Completed

Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain, Germany, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type b

Peru
GlaxoSmithKline

Completed

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b | Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine

Poland, United Kingdom
GlaxoSmithKline

Completed

Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea

Tetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis Vaccines | Poliomyelitis

Korea, Republic of
GlaxoSmithKline

Completed

A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers

Diphtheria

Spain, Germany, Italy
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis

Colombia, Costa Rica
Sanofi Pasteur, a Sanofi Company

Completed

A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis

Colombia, Costa Rica
GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines

Infections, Meningococcal | Meningococcal Vaccines

Estonia, Germany, Spain
Sanofi Pasteur, a Sanofi Company

Completed

Database Surveillance Safety Study of PENTACEL® Vaccine

Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae

United States
GlaxoSmithKline

Completed

Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants

Tetanus | Diphtheria | Acellular Pertussis

Korea, Republic of
GlaxoSmithKline

Completed

Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Singapore
GlaxoSmithKline

Completed

Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Italy, Sweden, Finland
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants

Hepatitis B | Pertussis | Diphtheria | Polio | Haemophilus Influenzae Type b

Thailand
GlaxoSmithKline

Completed

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Dominican Republic
GlaxoSmithKline

Completed

Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose

Infections, Streptococcal

Singapore
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children

Tetanus | Diphtheria | Acellular Pertussis

China
GlaxoSmithKline

Completed

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Hepatitis A

United States
Sanofi Pasteur, a Sanofi Company

Completed

Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines

Pertussis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis

Mexico
GlaxoSmithKline

Completed

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age

Infections, Streptococcal

Singapore, Malaysia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers

Meningococcal Infection

Mexico, Lebanon

Search clinical trials for: Infanrix™-IPV/Hib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations